QSBS in Connecticut: Rolling Conformity, 6.99% Top Rate, and What Stamford Fintech, New Haven Biotech, and Hartford Insurtech Founders Need to Know

Connecticut's rolling conformity to Section 1202: what it means for CT founders

Connecticut uses rolling conformity to the Internal Revenue Code — the state's income tax statute incorporates the IRC "as amended from time to time" rather than adopting it as of a fixed historical date. When Congress amends a federal tax provision, the change flows automatically into Connecticut law unless the Connecticut Legislature specifically decouples from it.¹

For §1202 purposes, Connecticut's rolling conformity means:

• The OBBBA's §1202 enhancements — the $15M exclusion cap (up from $10M), the tiered 3/4/5-year exclusion schedule (50/75/100% for post-July 4, 2025 stock), and the $75M gross assets threshold (up from $50M) — applied in Connecticut automatically when OBBBA was enacted, without any Connecticut legislative action.
• Connecticut has not decoupled from §1202 in any legislation through September 2026. The full §1202 exclusion applies at the state level.
• If Congress further amends §1202 in the future, those changes will also flow into Connecticut law automatically — unless the General Assembly specifically decouples.

This is in contrast to California, which repealed its §1202 conformity statute in 2013 and taxes the full §1202-excluded gain at California rates up to 13.3% — regardless of federal exclusion. It is also in contrast to Oregon, which SB 1507 (April 2026) decoupled from §1202 entirely, effective retroactively to January 1, 2026. Connecticut has taken neither of those steps. The rolling conformity mechanism is Connecticut's default: adopt unless the General Assembly explicitly opts out. Connecticut has not opted out of §1202.

For a neighboring comparison, Massachusetts also conforms to §1202 — but Massachusetts uses a static IRC reference date (January 1, 2024) rather than rolling conformity. This creates a gap: the OBBBA's July 2025 enhancements (the $15M cap and tiered schedule) may not automatically apply at the Massachusetts level for post-July 2025 stock, since Massachusetts must pass conformity legislation to capture them. Connecticut has no such gap: rolling conformity picks up OBBBA automatically. See the Massachusetts QSBS guide for the MA-specific analysis.

For the complete OBBBA §1202 breakdown — the tiered exclusion schedule, the gross assets increase to $75M, and the pre/post comparison — see the OBBBA QSBS guide. For how the holding period clock starts for ISOs, RSAs, SAFEs, and convertible notes, see the holding period guide.

Connecticut's 6.99% top rate and what Section 1202 saves CT founders

Connecticut taxes capital gains as ordinary income — there is no preferential long-term capital gains rate at the state level. Capital gains are subject to Connecticut's standard progressive income tax brackets, with a top marginal rate of 6.99% on income above $500,000 for single filers ($1,000,000 for married filing jointly).²

Connecticut's 2026 income tax brackets for single filers:

For a startup founder with a large QSBS exit — whether $5M, $10M, or $15M — virtually the entire gain falls into the top 6.99% bracket, since the $500K threshold is crossed almost immediately. The blended-rate effect of the lower brackets on a large gain is minimal: on a $15M gain, the marginal and effective Connecticut rates are both essentially 6.99%.

The §1202 exclusion eliminates Connecticut income tax entirely on the excluded gain:

• Pre-OBBBA $10M qualifying exit (5-year hold, $50K basis): CT state tax savings = $10M × 6.99% = $699,000
• Post-OBBBA $15M qualifying exit (5-year hold): CT state tax savings = $15M × 6.99% = $1,048,500

These amounts stack on top of the federal tax eliminated by the exclusion. Federal LTCG at 20% plus NIIT at 3.8% on a fully excluded $15 million gain eliminates approximately $3,570,000 in federal tax at the 5-year mark. The combined federal-plus-Connecticut benefit on a $15M post-OBBBA qualifying exit exceeds $4.6 million in total tax eliminated for a Connecticut-domiciled founder.

No local income tax in Connecticut

Connecticut cities and towns do not impose a personal income tax. Greenwich, Stamford, Hartford, New Haven, Bridgeport, Fairfield, Westport, and all other Connecticut municipalities collect property taxes, sales taxes, and local fees — but no city wage tax, local income tax, or local capital gains surcharge. A Connecticut founder's state-and-local income tax burden on QSBS gains consists entirely of the Connecticut state rate — and zero under full §1202 exclusion.

This distinguishes Connecticut from New York City, where NYC residents pay city income tax of up to 3.876% on top of New York State income tax. A Connecticut-based founder with a $15M QSBS exit and full exclusion owes $0 in Connecticut state and local income tax; a comparable NYC-resident founder — even with New York State's §1202 conformity — would owe 3.876% NYC income tax on any non-excluded gain. Note that Connecticut commuters who work in New York City but are domiciled in Connecticut are New York non-residents for city tax purposes; NYC non-resident earned income is subject to a city earnings tax, but capital gains from QSBS are not New York-source income for non-residents and are not taxable by New York City on a Connecticut-resident's QSBS gain.

Stamford fintech, VC, and PE: the §1202(e)(3)(B) banking and financing exclusion analysis

Stamford, Greenwich, and the Fairfield County corridor are home to one of the world's densest concentrations of hedge funds, private equity firms, venture capital funds, and financial technology companies. Connecticut's Financial Services sector employs hundreds of thousands of people and generates some of the largest equity compensation events in the state. This concentration creates significant §1202(e)(3)(B) excluded-industry risk that does not arise in most technology markets.

IRC §1202(e)(3)(B) excludes businesses "in the field of banking, insurance, financing, leasing, investing, or similar financial services." The analysis turns on whether the company performs financial services or provides software and technology to companies that do.

Financial technology software and infrastructure: generally qualified

Connecticut fintech companies that build and license technology — rather than directly performing regulated financial services — are generally not excluded under §1202(e)(3)(B):

• Payments and transaction processing software: Companies that build and sell payment APIs, ACH automation tools, card issuance platforms, or transaction settlement software to financial institutions — where the company's revenue is from software licensing or SaaS fees, and the company itself does not hold money or take on credit risk — are generally in the technology field. §1202(e)(3)(B) excludes the business of banking and financing, not the business of building software for banks and financial companies.
• Regulatory technology (regtech) and compliance software: B2B SaaS platforms that automate KYC, AML, fraud detection, OFAC screening, or regulatory reporting — where the company sells software subscriptions to financial institutions — are not performing banking or financing. The company's value is in its software platform and data models, not in a financial service it delivers to consumers.
• Trading infrastructure and market data platforms: Companies that sell order management systems, market data feeds, algorithmic trading software, or risk analytics platforms to hedge funds or asset managers — where the company's revenue is from technology licenses, not from managing client assets or executing trades on its own account — are generally in the software field. Providing tools to investors is not the same as being in the investing business.
• Insurance technology platforms: Companies that build software for underwriting automation, claims processing, policy administration, or distribution (to insurance carriers, not direct to insureds) — where the company sells software and the insurer carries the insurance risk — are generally in the software business and not the insurance field under §1202(e)(3)(B).

Financial services companies: excluded

Connecticut-based financial services businesses that perform the regulated activities themselves — rather than sell technology to those who do — are excluded under §1202(e)(3)(B):

• Hedge funds, private equity firms, and venture capital funds — their primary business is investing capital, which falls squarely within "investing" under §1202(e)(3)(B). Equity held in a general partner entity of a VC or PE fund is generally ineligible for §1202 treatment because the GP entity's business is investing.
• Registered investment advisers and wealth management firms — even technology-enabled or fee-only firms — whose primary revenue is from managing client portfolios or providing investment advice are in the investing business.
• Online lenders, marketplace lenders, and factoring companies that originate and fund loans on their own balance sheet — earning interest income and taking on credit risk — are in the financing business regardless of the efficiency of their technology platform.
• Insurance carriers, managing general agents (MGAs), and licensed insurance producers whose primary revenue is insurance premiums, reinsurance, or insurance commissions — excluded even if they use sophisticated technology platforms for underwriting.

The gray zone: embedded finance and dual-revenue-stream companies

Connecticut has a number of companies with hybrid business models — particularly in Stamford and Greenwich — where software and financial services revenues are both material. These require factual §1202(e)(3)(B) analysis:

• A fintech company that charges SaaS fees for a payment platform but also holds a money transmission license and earns float income from held funds may be partially or wholly in the financial services field depending on revenue mix and how the business is positioned.
• An employee benefits technology company that automates 401(k) enrollment and investment selection — but also acts as a registered investment adviser to plan participants — may have its §1202 eligibility affected by the advisory function.
• A real estate technology company that includes a mortgage lending or investment syndication component — where the company participates in the financing or investing activity rather than merely providing software to those who do — faces heightened §1202(e)(3)(B) risk.

For any Connecticut company with a meaningful financial services revenue stream, a written §1202(e)(3) legal opinion from qualified tax counsel is essential before planning any gifting, trust structure, or holding-period strategy around the §1202 exclusion. See the excluded industries guide for the full §1202(e)(3) statutory framework.

New Haven biotech and life sciences: the §1202(e)(3)(A) health exclusion analysis

New Haven and the Greater Hartford area are home to one of the most productive biotech and life sciences clusters on the East Coast, anchored by Yale University's research programs and commercialization ecosystem. Connecticut produced multiple notable biotech and pharmaceutical exits in the decade through 2026. Yale's Office of Cooperative Research spins out dozens of companies per year — many of which may hold §1202-eligible stock from their earliest C corporation stage.

IRC §1202(e)(3)(A) excludes businesses "in the field of health" — specifically those whose principal asset is "the reputation or skill of 1 or more of its employees." The provision targets clinical care delivery companies, not technology or research companies serving the health sector.

Biotech, pharma R&D, and medical devices: generally qualified

Life sciences companies that conduct research, development, and manufacturing — rather than directly delivering clinical care to patients — are generally not excluded under §1202(e)(3)(A):

• Pharmaceutical and biopharmaceutical R&D companies: Companies discovering and developing small-molecule or biologic drug candidates — where the company's value is in its pipeline, IP, and scientific platform, not in physician care rendered to patients — are generally in the pharmaceutical or scientific research field, not the health services field. The §1202(e)(3)(A) exclusion focuses on whether the company's principal asset is the skill of employees rendering personal services to patients; a preclinical or clinical-stage pharma company's principal asset is its IP and drug candidates.
• Medical device designers and manufacturers: Connecticut companies that design, prototype, and manufacture FDA-cleared medical devices — surgical instruments, diagnostic systems, monitoring equipment, implantable devices — are primarily manufacturers. Their principal asset is proprietary technology and manufacturing capability, not clinical skills rendered to patients.
• Clinical research organizations (CROs) — partial analysis: CROs that manage clinical trials for pharmaceutical sponsors operate in a nuanced space. If the CRO's primary service is research protocol management and data collection (a scientific/administrative function), it may qualify. If it provides clinical care to patients as part of the trial — employing physicians who deliver health services — the §1202(e)(3)(A) risk increases. A written §1202(e)(3) legal opinion is warranted for CRO founders before planning around the exclusion.
• Digital therapeutics and health software platforms: Companies that build FDA-cleared software platforms for disease management, behavioral health support, or patient engagement — where the product is the software and the company employs engineers and data scientists, not licensed clinicians delivering care — are generally in the software field. The company's principal asset is the technology, not the health skill of employee clinicians.

Clinical care delivery: excluded

Connecticut companies whose primary business is delivering health care services to patients are excluded under §1202(e)(3)(A), regardless of how technology-enabled those services are:

• Multi-specialty group practices, hospital management companies, and physician practice management firms — where the company's principal assets are the physicians or other licensed clinicians delivering care
• Telehealth and virtual care platforms whose primary revenue comes from clinical encounters — particularly where the company employs licensed physicians or mid-level providers who deliver care as the core product
• Home health, behavioral health, and therapy companies where licensed clinicians deliver the primary service to patients
• Connecticut's large hospital system affiliates and academic medical center management entities — excluded under §1202(e)(3)(A) regardless of their technology investments

For a detailed analysis of how the §1202(e)(3)(A) health exclusion applies to specific company types — including PLR guidance and borderline software-plus-care models — see the excluded industries guide.

Hartford insurtech: the §1202(e)(3)(B) analysis for software-for-insurance companies

Hartford has been the insurance capital of the United States for over two centuries. Today it is also home to a growing cluster of insurtech companies — startups that build software for the insurance industry without being insurance companies themselves. The distinction between a licensed insurance carrier (excluded under §1202(e)(3)(B)) and an insurtech software company (potentially qualifying) is consequential for Connecticut founders.

§1202(e)(3)(B) excludes businesses in the field of "insurance" — and insurance carriers, managing general agents, licensed producers, and reinsurers are excluded regardless of how technology-enabled their operations are. However, companies that build software tools for the insurance industry without holding insurance licenses or underwriting risk are generally in the software field, not the insurance field:

• Policy administration systems (PAS) vendors: Companies that license policy management software to carriers — where the company earns SaaS revenue and the carrier owns the insurance risk — are generally in the technology field. The company's business is software; the carrier's business is insurance.
• Underwriting automation and AI platforms: Companies that sell machine learning or rules-engine software to carriers for underwriting decisioning — where the software makes recommendations and the carrier makes the final underwriting decision and holds the risk — are in the software business. Providing tools that improve underwriting is not the same as performing underwriting.
• Claims management technology: B2B software for claims intake, triage, valuation, and settlement automation — licensed to carriers or TPAs on a SaaS or per-claim basis — is generally in the technology field.
• Licensed MGAs and program administrators: If the insurtech company holds an MGA license, binds coverage on behalf of a carrier, and earns commission on premiums, the company is performing insurance distribution — a function specifically within the §1202(e)(3)(B) "insurance" exclusion. Even a technology-forward MGA model creates §1202 exclusion risk if the company's revenue is substantially from insurance placement activities.

OBBBA's 28% rate trap for 3-year and 4-year holds in Connecticut

Under OBBBA, founders holding post-July 4, 2025 stock have a tiered exclusion: 50% at 3 years, 75% at 4 years, 100% at 5 years. This gives founders earlier liquidity options with partial exclusion — but the non-excluded portion of §1202 gain at the 3-year and 4-year tiers is not taxed at the standard 20% long-term capital gains rate. Under §1(h)(4)(A)(i), partially excluded §1202 gain is subject to a maximum federal rate of 28% on the taxable portion. Connecticut income tax at 6.99% also applies to the non-excluded portion.

Pre-OBBBA stock (issued before July 4, 2025) still faces the original all-or-nothing 5-year cliff. A 4-year hold produces $0 exclusion; a 5-year hold produces 100% exclusion (up to the $10M cap or 10× basis). See the OBBBA guide for the full rate-trap analysis.

Connecticut's Angel Investor Tax Credit: stacking a state credit with the §1202 exclusion

Connecticut administers the Angel Investor Tax Credit Program through Connecticut Innovations — a state-backed entity that supports early-stage Connecticut startups. The program provides accredited investors with a 25% credit against Connecticut state income tax when they invest between $25,000 and $400,000 in a Qualified Connecticut Business (QCB). The maximum credit per company investment is $100,000 (on a $400,000 investment); the maximum lifetime credit for any investor is $500,000.³

How the AITC stacks with §1202

The Connecticut AITC and the §1202 QSBS exclusion can stack — the AITC reduces current-year Connecticut income tax, while §1202 eliminates future Connecticut income tax on exit gain. A Connecticut-based angel investor who invests $100,000 in a qualifying company receives a $25,000 credit against Connecticut income tax in the investment year, and — if all §1202 qualification tests are met — can later exclude the capital gain from both federal and Connecticut income tax at exit.

The key limitation is that the Qualified Connecticut Business requirements for AITC are narrower than §1202 eligibility requirements:

• QCB requires gross revenues below $1 million in the most recent year — a very early-stage threshold that may not apply to companies that have progressed to a §1202-qualifying exit
• QCB requires fewer than 25 employees with at least 75% Connecticut residents
• QCB requires the company to have operated in Connecticut for fewer than seven consecutive years at the time of the AITC application
• QCB limits prior angel investments to $2 million

In practice, companies that still qualify for AITC are at a very early stage — often pre-revenue or early revenue. Most companies that generate material QSBS-eligible gains will have outgrown QCB status by the time of exit. The AITC is most valuable as an investment-year tax credit for Connecticut angels backing local startups in seed to early-Series A stage — not as a planning tool for companies approaching a large liquidity event. Investors who benefit from both AITC and §1202 on the same investment typically do so in very small, early-stage CT startups where the exit is modest.

Application process and timing

The AITC requires pre-investment approval: the company must be designated as a QCB by Connecticut Innovations, and the investor must apply and receive a tax credit reservation number before making the investment. Retroactive applications are not permitted. Investors who make investments without first obtaining AITC approval cannot claim the credit regardless of QCB eligibility. For more information, see Connecticut Innovations' Angel Investor Tax Credit program page.

Connecticut estate tax and OBBBA: coordinating QSBS planning with CT estate planning

Connecticut is the only state in the United States with an estate tax that conforms to the federal exemption amount. The federal estate tax exemption was permanently raised to $15 million per individual under OBBBA — eliminating the scheduled 2026 TCJA-sunset that would have cut the exemption to approximately $7 million. Because Connecticut conforms to the federal exemption amount, Connecticut's estate tax exemption is aligned with the federal amount.⁴

For Connecticut-based QSBS founders and investors, this has meaningful planning implications:

• A Connecticut founder with a $15M QSBS gain who holds the stock through death — rather than selling during life — could potentially eliminate both federal and Connecticut capital gains tax on the unrealized gain through the estate tax step-up in basis under §1014. However, §1202 exclusion is only available to the original holder or a donee who acquired shares through a gift (§1202(h)(2)) — there is no §1202(h) provision for inherited shares to carry over QSBS status to the heir. An heir who receives QSBS through a bequest gets a stepped-up basis but does not inherit the §1202 exclusion right; if the heir sells, the gain is measured from the stepped-up basis but the §1202 exclusion is not available.
• This creates a planning tension: gifting QSBS shares before death preserves the §1202 exclusion (the donee receives the shares with QSBS status and holding period carryover under §1202(h)(2)) but sacrifices the step-up in basis at the donor's death. For large qualifying QSBS positions, the §1202 exclusion is generally more valuable than the basis step-up — but the interaction requires coordinated estate planning.
• Connecticut's estate tax conformity with the federal $15M exemption means that for most Connecticut QSBS founders, the estate tax and QSBS intersection is primarily a federal planning issue, not a separate state estate tax problem on top of it.

For QSBS gifting mechanics and trust structures — including pre-LOI timing windows and grantor versus non-grantor trust distinctions — see the gifting and stacking guide and the trusts guide.

Connecticut QSBS worked examples

Connecticut versus peer states: QSBS comparison

Connecticut's 6.99% top rate and rolling §1202 conformity place it among the most favorable income-tax states for QSBS planning in the Northeast. While New York and New Jersey offer slightly higher dollar savings at the state level (due to higher top rates), New York carries ongoing decoupling risk and NYC residents pay additional city income tax on non-excluded gain. Connecticut founders who are eligible for full §1202 exclusion pay $0 in state and local income tax on the excluded gain — comparable to rolling-conformity states like Illinois, and substantially better than Pennsylvania (non-conforming) or California (repealed §1202 in 2013).

Planning priorities for Connecticut founders

1. Resolve the §1202(e)(3) excluded-industry question for Stamford fintech, New Haven biotech, and Hartford insurtech companies

Connecticut's rolling §1202 conformity only protects the exclusion if the company's stock actually qualifies under the qualified-trade-or-business test. For Stamford and Fairfield County founders in fintech, payments, or financial services adjacency, §1202(e)(3)(B)'s banking and financing exclusion is the primary risk — the analysis turns on whether the company performs financial services or sells software to companies that do. For New Haven biotech and life sciences founders, §1202(e)(3)(A)'s health exclusion requires distinguishing R&D and software (generally qualifying) from clinical care delivery (excluded). For Hartford insurtech founders, §1202(e)(3)(B)'s insurance exclusion requires distinguishing software-for-insurance (generally qualifying) from licensed insurance distribution or MGA activities (excluded). Get a written §1202(e)(3) opinion from qualified tax counsel before any gifting, trust planning, or holding period optimization. See the excluded industries guide.

2. Verify all eight qualification tests at issuance — not at the time of sale

The §1202 exclusion depends on facts at the moment shares were issued. C corporation status (LLCs, S-Corps, and partnerships cannot issue QSBS), gross assets below $50M pre-OBBBA or $75M post-OBBBA at issuance, the active 80% business test, original issuance to an eligible shareholder, and the holding period must all be satisfied at issuance. Connecticut founders who received shares through an LLC-to-C-Corp conversion or an S-Corp election revocation must verify that the conversion date — not the original LLC unit grant date — is the clock-start date, and that gross assets were below the applicable threshold at the time of the post-conversion share issuance. See the Section 1202 checklist.

3. Reach the 5-year mark for post-OBBBA stock before any sale

On a $15M post-OBBBA qualifying exit, the difference between a 4-year hold and a 5-year hold is $1,449,877 in total taxes — including $261,352 in Connecticut state income tax that goes to zero at year 5. The federal 28% rate trap on the non-excluded portion at 4 years is the larger component, but Connecticut's 6.99% rate makes the state element material. If a transaction timeline has any flexibility — whether an acquisition letter of intent, a tender offer window, or an IPO lockup expiry — the holding period math should inform the calendar before any binding commitment is made.

4. Plan gifting and trust structures before any transaction is signed

Connecticut's rolling §1202 conformity means a Connecticut-resident donee has their own §1202 exclusion cap on gifted QSBS shares — up to $15M post-OBBBA per donee under §1202(h)(2). A Connecticut founder with a $45M qualifying QSBS gain who gifts shares to two Connecticut-resident family members before signing a definitive agreement can potentially triple the available federal-plus-Connecticut exclusion. The gift must occur before any binding obligation to sell — after a letter of intent or merger agreement is signed, anticipatory assignment of income rules apply and the tax benefit may be lost. See the gifting and stacking guide for timing rules and the trusts guide for non-grantor trust stacking strategies.

5. Coordinate §1202 planning with Connecticut estate planning under the OBBBA-aligned exemption

Connecticut's estate tax conforms to the federal exemption — now permanently $15M per person under OBBBA. For Connecticut QSBS holders with estates approaching or above $15M, the interaction between the §1202 exclusion (available during life to original holders and donees) and the basis step-up at death (available to heirs but without §1202 carryover) should be modeled explicitly. In most cases, the §1202 exclusion during life is more valuable than the basis step-up at death — but the precise calculus depends on estate size, family goals, and charitable intent. A fee-only advisor who works across tax, estate, and investment planning is best positioned to coordinate these decisions before a transaction closes.

6. Consider the Connecticut Angel Investor Tax Credit if backing early-stage CT startups

Connecticut-based angel investors who invest $25,000 to $400,000 in Qualified Connecticut Businesses can receive a 25% state income tax credit in the investment year — stacking on top of any future §1202 exclusion on exit gain. The AITC requires pre-investment approval through Connecticut Innovations; the application must precede the investment. The AITC's QCB requirements (sub-$1M revenue, fewer than 25 employees) limit it to very early-stage companies, but for angels investing in seed-stage Connecticut startups, it can materially reduce the effective cost of qualifying investments while preserving the §1202 exclusion opportunity on the back end.

Talk to a QSBS advisor about your Connecticut situation

Connecticut's rolling IRC conformity and the §1202 exclusion can eliminate up to $1,048,500 in Connecticut state tax on a $15M qualifying exit — but the §1202(e)(3) excluded-industry analysis for Stamford fintech, New Haven biotech, and Hartford insurtech founders; the federal qualification tests; the OBBBA tiered holding period rules; and the gifting, trust, and estate planning window before a transaction all require professional review. A fee-only financial advisor who specializes in QSBS and founder liquidity can confirm qualification, model the full federal-plus-Connecticut tax picture, coordinate the pre-transaction planning window, and integrate QSBS planning with estate and charitable goals before the opportunity closes.

Fee-only focus - No obligation - Privacy-minded matching - Built for seven-figure planning decisions